KUALA LUMPUR, Malaysia, July 24, 2025 /PRNewswire/ — The Aesthetic Medicine & Surgery Conference & Exhibition (AMSC) returns for its fourth edition from August 6-7, 2025, with an expanded focus on global participation and advanced education. Held at the Kuala Lumpur Convention Centre (KLCC), AMSC 2025 will feature over 160 world-class speakers, 200 international brands, and 20 supporting partners, including 13 medical societies and 7 industry collaborators. More than 1,600 delegates from around the world are expected, with highlights including clinical innovation updates, live demonstrations, and expert insights from speakers representing over 30 countries.

“AMSC Malaysia 2025 represents a global crossroads for aesthetic medicine, where regional insights meet international expertise. This year, we are not just sharing techniques, we are also building a collaborative future for the field by fostering dialogue, discovery, and innovation across borders,” said Dr Tingsong Lim, President of the Malaysian Society of Aesthetic Medicine (MSAM) and Scientific Director of AMSC.

Elevating Aesthetic and Regenerative Care for Diverse Needs

AMSC Malaysia 2025 will explore a wide range of cutting-edge topics in aesthetic and regenerative medicine. These include Periorbital Rejuvenation, focusing on advanced techniques using fillers, threads, and devices to treat tear troughs and under-eye ageing; Melasma Management, with evidence-based protocols combining lasers, topicals, and regenerative treatments tailored for Asian skin; Facelift Techniques, covering both surgical and non-invasive approaches such as thread lifts, energy-based tightening, and facial sculpting; Longevity Medicine, exploring anti-ageing strategies that utilise semaglutide, hormones, peptides, and polydeoxyribonucleotides (PDRN); Regenerative Aesthetics, highlighting the use of exosomes, stem cells, and PRP to restore skin quality and stimulate collagen; Scar Treatment, featuring multi-modal solutions using lasers, injectables, and biostimulators for acne scars and post-surgical healing; and more.

Through these sessions, delegates will gain in-depth knowledge of current clinical trends, master advanced injection and device-based techniques, and learn how to apply combination approaches for improved patient outcomes. The conference provides ample opportunities for attendees to explore innovations in regenerative medicine, deepen their understanding of tailored treatments for diverse skin types and enhance their ability to meet the growing demands of specialised patient segments, including male aesthetics and ageing populations.

This year’s AMSC welcomes a distinguished line-up of global experts who are redefining the standards of aesthetic and regenerative medicine:

• DrTingsong Lim (Malaysia) is an aesthetic doctor who has been involved in academic research and training on Asian facial and body aesthetics, clinical application of filler rheology, Facial Overfilled Syndrome, pigmentary disorders, energy-based medicine, and regenerative medicine. He is the President of the Malaysian Society of Aesthetic Medicine and a frequent speaker at top regional and international conferences.
• DrGiovanni Salti (Italy) is a renowned plastic surgeon who specialises in fat surgery and regenerative fat therapy and has extensive global experience in nonsurgical cosmetic procedures. Over the last 20 years, he has been invited to numerous international scientific congresses and meetings on soft tissue fillers, botulinum toxin, cellulite, lasers, and minimally invasive aesthetics.
• Dr Nino Reisener (Germany) is an aesthetic doctor with global clinical exposure who has performed over 25,000 injections. He brings deep industry knowledge from over eight years of experience with one of the largest companies in the injectable industry, as well as more than 300 hours of clinical mentorship.
• DrMonika Kavkova (Czech Republic) is an internationally certified expert in aesthetic, anti-ageing, and regenerative medicine, as well as dermatologic surgery. She is the owner and leading doctor at BE ELITE CLINIC in Prague and the scientific board director of Prague LAB (Aesthetic Dialogue international symposium).
• DrKyu-Ho Yi (South Korea) is an anatomist and adjunct professor at Yonsei University, with over 40 published papers. He is the Director of Maylin Clinic and Academic Director of the Korean Association of Laser, Dermatology, and Trichology.
• DrDo Young Rhee (South Korea) is the Director of Heal House Dermatology and the Academic Director of KOREADERMA. A pioneer in combination therapies for Asian skin, he regularly speaks at the Aesthetic and Anti-Aging Medicine World Congress (AMWC), International Master Course on Aging Science (IMCAS), and KOREADERMA.
• DrSusan Cheong (Macau SAR) is a plastic surgeon and PhD candidate at Southern Medical University, serving as International Liaison of the Chinese Association of Plastics and Aesthetics (CAPA). She bridges clinical aesthetics and scientific innovation, focusing on ECM-based regenerative strategies and anti-ageing innovations.

The PINOKIO Surgical Zone Returns with Expanded Hands-On Training

Returning for its eighth edition in Malaysia, the PINOKIO Surgical Zone at AMSC 2025 brings back Korea’s leading surgical organisation for an expanded three-day programme from 6 to 8 August 2025. In a groundbreaking collaboration, AMSC partners with the Plastic Innovative Nasal Ormaxillofacial Korean International Organisation (PINOKIO) to deliver an immersive and focused surgical education experience tailored for professionals seeking to refine their techniques and deepen their anatomical understanding.

The agenda includes Day 1: Nose Surgery Focus, Day 2: Face and Chest Lift Techniques, and Day 3: Hands-on Cadaver Masterclass on Rhinoplasty and Surgical Facelift. Delegates will benefit from expert-led lectures, live cadaver dissections, and practical demonstrations guided by some of Asia’s most respected surgeons. Additionally, the zone features a curated exhibition showcasing the latest tools and innovations in facial, nasal, and chest aesthetic surgery.

Additionally, the exhibition hall will feature leading global brands such as Merz Aesthetics, Juvederm, Skinvive, Neauvia, Oligio, Gouri, Karisma, Multifrax, Sinclair, and Plinest, offering delegates hands-on access to the latest innovations in injectables, energy-based devices, and regenerative solutions.

For more information about the event and to register, visit www.amsc.com.my.

CHANGZHOU, China, July 24, 2025 /PRNewswire/ — On July 17, Bloomberg Green honored Trinasolar as the “Workplace for All” in Greater China, recognizing its commitment to employee development and innovation, as well as its efforts in fostering a sustainable culture of diversity and inclusion. The selection process, guided by rigorous international standards, highlights companies that excel in ESG performance, gender equality, and labor compliance, positioning them as global leaders in talent cultivation and sustainable growth.

Trinasolar upholds fair and transparent evaluation standards for performance reviews, promotions, talent selection, and training. It ensures equal opportunities for all employees while cultivating a workplace free from discrimination. In 2024, the company became a global signatory of the United Nations Women’s Empowerment Principles (WEPs), underscoring its commitment to advancing gender equality and workplace diversity. By the end of 2024, women accounted for 27.14% of Trinasolar’s workforce and 33.33% of its board of directors. Additionally, the company is committed to empowering socially vulnerable groups, including individuals with disabilities, by offering roles tailored to their physical needs, enabling them to realize their potential and personal value.

Labor protection remains central to Trinasolar’s corporate responsibilities. The company strictly complies with local labor laws, has established robust grievance and complaint procedures to safeguard employee rights, and has implemented comprehensive occupational health and safety measures. In addition to providing competitive compensation and benefits, Trinasolar prioritizes both the physical and mental well-being of its employees. In 2024, the company invested 90.64 million RMB in occupational health and safety initiatives and ensured that 100% of its employees were covered by employer liability and work injury insurance.

Trinasolar prioritizes innovation and talent development. In 2024, the company allocated 6.92% of its total revenue to R&D and had implemented a specialized training program in collaboration with leading institutions including the University of New South Wales, the University of Oxford, and Fraunhofer. These programs enhance the innovation capacity of R&D teams and strengthen industry-academic partnerships. Last year, Trinasolar achieved a 100% training coverage rate, with over 1.7 million total training hours, laying a strong foundation for talent development in the renewable energy sector.

Trinasolar believes that an inclusive and trustworthy workplace is essential for long-term value creation and sustainable corporate growth. Looking ahead, the company will continue to foster inclusive workplace, ensure fair labor practices and employee well-being, and collaborate with its global team to build a sustainable, net-zero future.

In 2025, the Lab has yielded two new U.S. Granted Patents, open-sourced a key AI development platform, and earned a Gold Award from GECCO

TEANECK, N.J., July 24, 2025 /PRNewswire/ — Cognizant (Nasdaq: CTSH) today announced that its AI Lab has been granted two new U.S. patents and a gold award for a research paper on “Realizing Human Expertise through AI” presented this month at GECCO (Genetic and Evolutionary Computation Conference) in Malaga, Spain.

Cognizant’s AI Lab displays 59 patents, with space for the 23 pending patents. The Lab celebrates each inventor with a U.S. Patent plaque and a FunkoPop figurine of their choice.

“Being granted two new U.S. patents in the first half of 2025—bringing our AI Lab’s U.S. total to 59 with 23 more patents pending—underscores our relentless pace of innovation,” said Babak Hodjat, CTO of AI at Cognizant. “Couple this with a Gold Award at GECCO and these milestones reflect our deep commitment to pioneering transformative AI technologies and turning cutting-edge ideas into real-world impact.”

The two latest patents highlight key innovations from Cognizant’s AI research:

• U.S. Patent No. 12,282,845 (issued on April 22, 2025) covers a method for Multi-objective Coevolution of Deep Neural Network Architectures, aimed at improving model performance and resource efficiency. The method’s application ranges from medical image classification to natural language processing.
• U.S. Patent No. 12,292,944 (issued on May 6, 2025) outlines a method for optimizing loss functions through Taylor Series Expansion, aiming to improve training efficiency and enhance model robustness, especially is data-limited scenarios.¹

These innovations, developed by Cognizant’s researchers including Dr. Jason Liang, Dr. Elliot Meyerson and Professor Risto Miikkulainen, reinforce Cognizant’s leadership in pushing the boundaries of AI and machine learning.

To make the promise of artificial intelligence both more practical and broadly accessible, earlier this year, Cognizant’s AI Lab open sourced its Neuro AI Multi-Agent Accelerator. Neuro AI helps businesses accelerate their development and adoption of AI agents, transforming their business processes for adaptive operations, real-time decision-making, and personalized customer experiences tailored to client-defined objectives and oversight.

The Cognizant AI Lab, which opened its San Francisco-based flagship AI research facility in March 2024, has also been honored with the Gold Award for Human-Competitive Results at GECCO 2025 for its groundbreaking work on RHEA (Realizing Human Expertise through AI). Developed by Dr. Elliott Meyerson and Professor Risto Miikkulainen RHEA employs evolutionary AI to distill and recombine hundreds of models generated by human expert teams—most notably those submitted to the XPRIZE Pandemic Response Challenge—into refined decision strategies. In a rigorous evaluation, RHEA surpassed the performance of individual human submissions, realizing the latent potential even in incompletely developed human ideas, resulting in innovative pandemic policy recommendations. This milestone underlines Cognizant’s leadership in harnessing global human expertise to drive next‑generation AI solutions.

Risto Miikkulainen, VP of Research and Professor of Computer Science at UT Austin, said, “RHEA is a powerful example of how evolutionary AI can amplify global human intelligence—not just by matching expert solutions, but by going beyond them to discover novel, high-impact strategies. This recognition by the Humies Award committee reinforces the promise of population-based AI as a foundation for solving the world’s most complex challenges.”

About Cognizant 
Cognizant (Nasdaq: CTSH) engineers modern businesses. We help our clients modernize technology, reimagine processes and transform experiences so they can stay ahead in our fast-changing world. Together, we’re improving everyday life. See how at www.cognizant.com or @cognizant.

About the Cognizant AI Lab
The mission of the Cognizant AI Lab is to maximize human potential with Decision AI, a form of AI that combines generative AI, multi-agent architecture, deep learning, and evolutionary AI to create sophisticated decision-making systems. Decision AI powers Cognizant’s Neuro^® AI platform, which is utilized by Fortune 500 companies and non-profits to discover new ways to exceed their goals. The platform enables organizations to rapidly build AI that optimizes decision-making, leading to revenue growth and societal progress. 

Led by AI pioneers Babak Hodjat and Risto Miikkulainen, the lab collaborates with institutions, academia, and technology partners to develop groundbreaking AI solutions responsibly. With over 120 patents (issued or pending) globally, the lab excels at combining scientific innovation with commercial application. It supports Cognizant’s goal of improving everyday life, focusing on business and AI-for-good applications.

CHANGZHOU, China, July 24, 2025 /PRNewswire/ — On July 17, Bloomberg Green honored Trinasolar as the “Workplace for All” in Greater China, recognizing its commitment to employee development and innovation, as well as its efforts in fostering a sustainable culture of diversity and inclusion. The selection process, guided by rigorous international standards, highlights companies that excel in ESG performance, gender equality, and labor compliance, positioning them as global leaders in talent cultivation and sustainable growth.

Trinasolar upholds fair and transparent evaluation standards for performance reviews, promotions, talent selection, and training. It ensures equal opportunities for all employees while cultivating a workplace free from discrimination. In 2024, the company became a global signatory of the United Nations Women’s Empowerment Principles (WEPs), underscoring its commitment to advancing gender equality and workplace diversity. By the end of 2024, women accounted for 27.14% of Trinasolar’s workforce and 33.33% of its board of directors. Additionally, the company is committed to empowering socially vulnerable groups, including individuals with disabilities, by offering roles tailored to their physical needs, enabling them to realize their potential and personal value.

Labor protection remains central to Trinasolar’s corporate responsibilities. The company strictly complies with local labor laws, has established robust grievance and complaint procedures to safeguard employee rights, and has implemented comprehensive occupational health and safety measures. In addition to providing competitive compensation and benefits, Trinasolar prioritizes both the physical and mental well-being of its employees. In 2024, the company invested 90.64 million RMB in occupational health and safety initiatives and ensured that 100% of its employees were covered by employer liability and work injury insurance.

Trinasolar prioritizes innovation and talent development. In 2024, the company allocated 6.92% of its total revenue to R&D and had implemented a specialized training program in collaboration with leading institutions including the University of New South Wales, the University of Oxford, and Fraunhofer. These programs enhance the innovation capacity of R&D teams and strengthen industry-academic partnerships. Last year, Trinasolar achieved a 100% training coverage rate, with over 1.7 million total training hours, laying a strong foundation for talent development in the renewable energy sector.

Trinasolar believes that an inclusive and trustworthy workplace is essential for long-term value creation and sustainable corporate growth. Looking ahead, the company will continue to foster inclusive workplace, ensure fair labor practices and employee well-being, and collaborate with its global team to build a sustainable, net-zero future.

In 2025, the Lab has yielded two new U.S. Granted Patents, open-sourced a key AI development platform, and earned a Gold Award from GECCO

TEANECK, N.J., July 24, 2025 /PRNewswire/ — Cognizant (Nasdaq: CTSH) today announced that its AI Lab has been granted two new U.S. patents and a gold award for a research paper on “Realizing Human Expertise through AI” presented this month at GECCO (Genetic and Evolutionary Computation Conference) in Malaga, Spain.

Cognizant’s AI Lab displays 59 patents, with space for the 23 pending patents. The Lab celebrates each inventor with a U.S. Patent plaque and a FunkoPop figurine of their choice.

“Being granted two new U.S. patents in the first half of 2025—bringing our AI Lab’s U.S. total to 59 with 23 more patents pending—underscores our relentless pace of innovation,” said Babak Hodjat, CTO of AI at Cognizant. “Couple this with a Gold Award at GECCO and these milestones reflect our deep commitment to pioneering transformative AI technologies and turning cutting-edge ideas into real-world impact.”

The two latest patents highlight key innovations from Cognizant’s AI research:

• U.S. Patent No. 12,282,845 (issued on April 22, 2025) covers a method for Multi-objective Coevolution of Deep Neural Network Architectures, aimed at improving model performance and resource efficiency. The method’s application ranges from medical image classification to natural language processing.
• U.S. Patent No. 12,292,944 (issued on May 6, 2025) outlines a method for optimizing loss functions through Taylor Series Expansion, aiming to improve training efficiency and enhance model robustness, especially is data-limited scenarios.¹

These innovations, developed by Cognizant’s researchers including Dr. Jason Liang, Dr. Elliot Meyerson and Professor Risto Miikkulainen, reinforce Cognizant’s leadership in pushing the boundaries of AI and machine learning.

To make the promise of artificial intelligence both more practical and broadly accessible, earlier this year, Cognizant’s AI Lab open sourced its Neuro AI Multi-Agent Accelerator. Neuro AI helps businesses accelerate their development and adoption of AI agents, transforming their business processes for adaptive operations, real-time decision-making, and personalized customer experiences tailored to client-defined objectives and oversight.

The Cognizant AI Lab, which opened its San Francisco-based flagship AI research facility in March 2024, has also been honored with the Gold Award for Human-Competitive Results at GECCO 2025 for its groundbreaking work on RHEA (Realizing Human Expertise through AI). Developed by Dr. Elliott Meyerson and Professor Risto Miikkulainen RHEA employs evolutionary AI to distill and recombine hundreds of models generated by human expert teams—most notably those submitted to the XPRIZE Pandemic Response Challenge—into refined decision strategies. In a rigorous evaluation, RHEA surpassed the performance of individual human submissions, realizing the latent potential even in incompletely developed human ideas, resulting in innovative pandemic policy recommendations. This milestone underlines Cognizant’s leadership in harnessing global human expertise to drive next‑generation AI solutions.

Risto Miikkulainen, VP of Research and Professor of Computer Science at UT Austin, said, “RHEA is a powerful example of how evolutionary AI can amplify global human intelligence—not just by matching expert solutions, but by going beyond them to discover novel, high-impact strategies. This recognition by the Humies Award committee reinforces the promise of population-based AI as a foundation for solving the world’s most complex challenges.”

About Cognizant 
Cognizant (Nasdaq: CTSH) engineers modern businesses. We help our clients modernize technology, reimagine processes and transform experiences so they can stay ahead in our fast-changing world. Together, we’re improving everyday life. See how at www.cognizant.com or @cognizant.

About the Cognizant AI Lab
The mission of the Cognizant AI Lab is to maximize human potential with Decision AI, a form of AI that combines generative AI, multi-agent architecture, deep learning, and evolutionary AI to create sophisticated decision-making systems. Decision AI powers Cognizant’s Neuro^® AI platform, which is utilized by Fortune 500 companies and non-profits to discover new ways to exceed their goals. The platform enables organizations to rapidly build AI that optimizes decision-making, leading to revenue growth and societal progress. 

Led by AI pioneers Babak Hodjat and Risto Miikkulainen, the lab collaborates with institutions, academia, and technology partners to develop groundbreaking AI solutions responsibly. With over 120 patents (issued or pending) globally, the lab excels at combining scientific innovation with commercial application. It supports Cognizant’s goal of improving everyday life, focusing on business and AI-for-good applications.

BELLEVUE, Wash. and SEOUL, South Korea, July 24, 2025 /PRNewswire/ — OSR Holdings, Inc. (NASDAQ: OSRH), a global healthcare company advancing biomedical and wellness innovation, today announced it has signed a term sheet (“Term Sheet”) with Woori IO Co., Ltd. (“WORIO”), a South Korean medical device company developing next-generation noninvasive glucose monitoring technology. The agreement sets forth certain key terms for a strategic acquisition of WORIO by OSR Holdings’ Korean affiliate, OSR Holdings Co., Ltd. (“OSRK”).

Under the proposed structure, WORIO will become a wholly owned subsidiary of OSRK. Shareholders of WORIO will receive newly issued shares of OSRK through the share exchange and may be eligible to convert them into OSRH common stock traded on NASDAQ, subject to certain conditions including “$10 per OSRH share” condition.

Specifically, WORIO shareholders may convert their OSRK shares into OSRH shares at a fixed exchange ratio of 1 OSRK share = 12.96 OSRH shares, provided that OSRH’s stock price reaches $10.00 at least once within three years following the signing of the Term Sheet. If this condition is not met, the parties have agreed to renegotiate in good faith.  The agreement includes a 6-month exclusivity period, during which OSRK will conduct confirmatory legal and financial due diligence with a target to complete this transaction within this exclusivity period.

WORIO’s proprietary platform uses near-infrared spectroscopy (NIRS) to measure glucose without needles, sensors, or skin penetration — representing a truly noninvasive alternative to today’s continuous glucose monitors (CGMs). Its solution aims to eliminate the burden of pain and daily finger pricks for millions of people with diabetes.  According to recent global market research, the blood glucose monitoring devices market is expected to exceed $40 billion by 2030, growing at a CAGR of 8–10%, driven by rising diabetes prevalence and the convergence of medical technology with consumer electronics. Demand for noninvasive and wearable monitoring systems is expected to be a major growth driver. Dexcom, one of the market leaders in minimally invasive CGM which is the current standard of care has more than $32 billion in market capitalization (as of July 11), underscoring the significant commercial potential of advanced glucose monitoring solutions. Noninvasive alternatives hold tremendous promise and are poised to become an integral part of diabetes management in the future.

WORIO has completed a proof-of-concept study with the Korea University Hospital (Guro) to validate the accuracy and effectiveness of its prototype devices and the data measured by them, based on which the company plans to enter a larger confirmatory trial to be registered with the Ministry of Food and Drug Safety (MFDS) of Korea for medical device approval pathway. WORIO’s noninvasive technology is well positioned to be integrated into wearable glucose monitoring devices such as smart watches — WORIO has been selected by Samsung Electronics’ innovative startup program (“C-Lab Outside”) in Q1 2025.

“We believe this initial milestone with Woori IO aligns strongly with our mission to accelerate breakthrough healthcare innovations with global impact,” said Peter Hwang, CEO of OSRH. “Woori IO’s breakthrough noninvasive glucose monitoring platform, coupled with its high-profile partnership with global companies, puts OSRH in a position to become a first mover in this fast-growing global market.”

Following the signing of this Term Sheet, both parties will proceed with due diligence and aim to execute definitive agreements within the 6 months exclusivity period.

About OSR Holdings, Inc.

OSR Holdings, Inc. (NASDAQ: OSRH) is a global healthcare holding company dedicated to advancing biomedical innovation approaches to health and wellness to support global health outcomes. Through its subsidiaries, OSRH is engaged in immuno-oncology, regenerative biologics, and medical device distribution. OSRH’s vision is to acquire and operate a portfolio of innovative healthcare and wellness companies, improving patient care through cutting-edge research and development. For more information, visit www.OSR-Holdings.com.

About Woori IO Co., Ltd.

Woori IO is a medical device company based in Jeonju, South Korea, focused on the development of noninvasive biosensing solutions. Its proprietary NIRS-based glucose monitoring system enables accurate, pain-free, and user-friendly diabetes management, with strong potential for wearable integration. For more information, visit www.Woori.io.

Contact:
Investor Relations
OSR Holdings, Inc.
Email: IR@osr-holdings.com 
Website: www.OSR-Holdings.com